Deals Of The Week: Clovis/Clavis; Novartis/Incyte; Jubilant/UAB/SRI ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.
Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine
Clovis takes over work on Clavis's pancreatic cancer drug and will develop a companion test to target patients who fare poorly on Lilly's current standard of care.
Cephalon Reinvention Puts Biologics Front And Center
Through several acquisitions and alliances completed over the last year, Cephalon has patched together a substantial pipeline of biologic drugs, an area of business the specialty pharma is ramping up as it looks to diversify its portfolio beyond wakefulness and pain